依维莫司为晚期乳腺癌治疗ppt课件.pptVIP

Overall survival data were immature at the time of this analysis: 137 events had been recorded at the time of database lock (17.2% in the combination arm vs 22.7% in the EXE arm), whereas 182 events were needed for the protocol-defined interim analysis of survival. Based on current event rates, the 182 events needed for interim analysis of survival are projected for December 2011, with projected event rates of 23.1% in the combination arm versus 29.3% in the EXE arm. * The increase in the frequency of some adverse events did not translate into differences in quality of life * Bone turnover markers are peptide fragments released as byproducts of bone remodeling or enzymes involved in bone turnover, and may reflect ongoing rates of bone resorption (eg, C-telopeptide of type I collagen [CTX]) or formation (eg, bone-specific alkaline phosphatase [BSAP], amino-terminal propeptide of type I collagen [P1NP]). The bar graph represents the percentage change in bone marker levels from baseline. Bars that extend below the x-axis represent bone marker levels that decreased relative to baseline levels. Conversely, bars that extend above the x-axis show bone marker levels that increased relative to baseline. Changes in bone marker levels relative to baseline reflect increased rates of bone turnover (resorption and formation). All AIs have been shown to increase bone turnover during adjuvant therapy, as assessed by levels of bone resorption and formation markers. In the TEAM trial, EXE treatment was associated with elevated levels of CTX and P1NP within 3 months, and the increases were sustained for up to 12 (P1NP) or 24 (CTX) months.1 The Intergroup Exemestane Study also showed elevated levels of bone resorption markers for the entire duration of EXE treatment.2 Although the effects of EVE alone on bone turnover markers are yet to be elucidated in humans, preclinical data show that mTOR inhibition with rapamycin can reduce TRAP activity (a measure of osteoclast-mediated bone